Cambios en las Subpoblaciones de Linfocitos B y T en el Título de Anticuerpos Anti-Acuaporina-4 tras el Tratamiento de un Brote Agudo con Inmunoglobulinas y Rituximab

Andrés, Clara de; Teijeiro, Roseta; Sáiz, Albert; Fernández, P.; Sánchez-Ramón, Silvia

doi:10.1016/j.nrl.2013.12.022

Cited by 4 publications

(6 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Continuous spinal cord thinning from C1 to T10 with no gadolinium uptake was demonstrated by the spinal cord MRI scan. [21] Radiologic progression with no clinical relapse resulted in mycophenolate mofetil increases after rituximab initiation, as reported in another study by Beres et al . At 6 months after the first course of RTX therapy in the 20-year-old female, the patient experienced a new mild spinal cord relapse confirmed by the presence of a new MRI enhancing lesion in the cervical spine.…”

Section: Impact Of Rituximab On Patients’ Magnetic Resonance Imagingmentioning

confidence: 65%

“…Persistence of NMO IgG-producing plasmablasts may elucidate some of the variability in clinical response. [21]…”

Section: Rituximabmentioning

confidence: 99%

“…Altogether, rituximab induces early benefit by eliminating or inhibiting pathogenic effector B-cells, whereas delayed and more sustained improvement depends on the preferential expansion of B-cells with regulatory functions. [2122] Quan et al . explore the impacts of high-dose methylprednisolone therapy and rituximab on circulating B-cells in 22 NMO patients.…”

Section: Effect Of Rituximab On the Level Of Cd19/cd20mentioning

confidence: 99%

“…reported a decreased mean EDSS score from 9 to 6.5, which was at the point, the patient had improved and was able to walk short distances with crutches. [21] The study of Collongues et al . contained 21 patients with mean EDSS of five reduced to three after therapy.…”

Section: Effect Of Rituximab On Patient's Expanded Disability Status mentioning

confidence: 99%

“…Imaging findings before and after rituximab therapy have been reported in some studies. [2132] Generally, it gives the impression that MRI findings suggest no new, active, or extended lesions after the treatment with rituximab[33] although worsening of symptoms along with enhancing injuries has also been reported. [34] de Andrés et al .…”

Section: Impact Of Rituximab On Patients’ Magnetic Resonance Imagingmentioning

confidence: 99%

See 4 more Smart Citations

Efficacy and safety of rituximab in neuromyelitis optica: Review of evidence

et al. 2017

View full text Add to dashboard Cite

Neuromyelitis optica (NMO) is an autoimmune inflammatory disease of the central nervous system with preferential involvement in the optic nerve and spinal cord with a widespread spectrum of clinical features; multiple therapeutic agents have been used with different results. Recent evidence points to B-cell-mediated humoral immunity in the pathogenesis of NMO. Rituximab targets the CD20 antigen on B-cells. Treatment leads to profound B-cell depletion, principally over an antibody-dependent cell cytotoxicity mechanism. The aim of our study was to review clinical trials to elucidate the impact of rituximab on the relapse rate, Expanded Disability Status Scale (EDSS), and progression of disability in NMO. We performed a comprehensive review of all studies that evaluated clinical and paraclinical effects of rituximab on NMO. MEDLINE-PubMed, Web of Sciences, EMBASE, and Cochrane databases up to June 2016 included in our searches. In addition, reference lists from articles identified by search as well as a key review article to identify additional articles included in the study. Rituximab targets the CD20 antigen on B-cells and decreases attack frequency and severity in patients with NMO; however, it does not remove attacks, even when modifying treatment to achieve B-cell depletion. Most of the investigations revealed that EDSS significantly in all patients with rituximab treatment will be decreased after treatment with rituximab. No new or enlarged lesions or pathological gadolinium enhancement was observed in serial brain and spinal cord magnetic resonance imaging, except for those observed concomitantly with clinical relapses and the median length of spinal cord lesions was significantly reduced after therapy. Rituximab targets the CD20 antigen and decreases attack frequency and severity in patients with NMO.

show abstract

Section: Impact Of Rituximab On Patients’ Magnetic Resonance Imagingmentioning

confidence: 65%

“…Persistence of NMO IgG-producing plasmablasts may elucidate some of the variability in clinical response. [21]…”

Section: Rituximabmentioning

confidence: 99%

Section: Effect Of Rituximab On the Level Of Cd19/cd20mentioning

confidence: 99%

Section: Effect Of Rituximab On Patient's Expanded Disability Status mentioning

confidence: 99%

Section: Impact Of Rituximab On Patients’ Magnetic Resonance Imagingmentioning

confidence: 99%

See 3 more Smart Citations

Efficacy and safety of rituximab in neuromyelitis optica: Review of evidence

et al. 2017

View full text Add to dashboard Cite

show abstract

Dynamics of AQP4 upon exposure to seropositive patient serum before and after Rituximab therapy in Neuromyelitis Optica: A cell-based study

Saha

Mukherjee

Guha

et al. 2021

Journal of Neuroimmunology

View full text Add to dashboard Cite

Three cases with chronic obsessive compulsive disorder report gains in wellbeing and function following rituximab treatment

Gallwitz,

Lindqvist,

Mulder

et al. 2024

Mol Psychiatry

View full text Add to dashboard Cite

Immunological aetiology is supported for a subgroup with obsessive compulsive disorder (OCD) and conceptualized as autoimmune OCD. The longitudinal clinical course is detailed for three severely ill cases with OCD and indications of immunological involvement with off-label rituximab treatment every six months. All cases showed clear and sustained gains regarding symptom burden and function for over 2.5 years. Brief Psychiatric Rating Scale and Yale-Brown Obsessive-Compulsive Inventory Scale scores decreased 67-100% and 44-92%, respectively. These complex cases, prior to rituximab, had very low functioning and disease duration has been eight, nine and 16 years respectively. All three patients had been unsuccessfully treated with at least two antidepressants or anxiolytics, one neuroleptic and cognitive behavioural therapy. Clinical phenotypes and findings were suggestive of possible autoimmune OCD. Indirect immunohistochemistry detected cerebral spinal fluid (CSF) antibodies in all three cases including a novel anti-neuronal staining pattern against mouse thalamic cells. Exploratory analyses of CSF markers and proteomics identified elevated levels of sCD27 and markers indicative of complement pathway activation when compared to CSF from healthy controls. Multidisciplinary collaboration, advanced clinical investigations and rituximab treatment are feasible in a psychiatric setting. The case histories provide a proof of principle for the newly proposed criteria for autoimmune OCD. The findings suggest that clinical red flags and biological measures may predict rituximab response in chronic treatment-resistant OCD. The report provides orientation that may inform the hypotheses and design of future treatment trials.

show abstract

Cambios en las Subpoblaciones de Linfocitos B y T en el Título de Anticuerpos Anti-Acuaporina-4 tras el Tratamiento de un Brote Agudo con Inmunoglobulinas y Rituximab

Abstract: Our findings confirm that, besides intrathecal humoral immune response against AQP4, B and T cell subsets are involved in the modulation of inflammation within and outside the central nervous system.

Cited by 4 publications

References 30 publications

Efficacy and safety of rituximab in neuromyelitis optica: Review of evidence

Efficacy and safety of rituximab in neuromyelitis optica: Review of evidence

Dynamics of AQP4 upon exposure to seropositive patient serum before and after Rituximab therapy in Neuromyelitis Optica: A cell-based study

Three cases with chronic obsessive compulsive disorder report gains in wellbeing and function following rituximab treatment

Contact Info

Product

Resources

About